This standard defines the labeling and packaging requirements used in Point 7 of the GIBQ 7-Point Standard. It is binding criteria for any vendor seeking GIBQ Verified certification.

This standard governs the physical product artifact as shipped — that is, the label adhered to the immediate product container and the immediate packaging in which the product is delivered. GIBQ evaluates these artifacts against the criteria below and renders a pass/fail determination.

This standard does NOT govern:

• Website copy, marketing materials, or product descriptions
• Customer reviews, testimonials, or third-party endorsements
• Affiliate or partner content
• The legal status or regulatory classification of the compound itself

These items are out of scope for the Label Standard. Any future expansion of GIBQ standards into these areas will be published as a separate, versioned standard.

The following four elements must appear on the physical product label. Absence of any required element results in a fail determination for Point 7.

The label must include the verbatim statement: “For Research Use Only. Not for Human Consumption.”

This statement must be legible and conspicuously placed. Variations or paraphrasing are not acceptable.

The label must identify the compound by its recognized scientific name. Acceptable formats include:

• International Nonproprietary Name (INN)
• United States Adopted Name (USAN)
• Established research designation used in published peer-reviewed literature

Trade names, marketing names, and ambiguous identifiers are not acceptable as the sole compound identity.

The label must specify the quantity of compound contained. Acceptable formats include:

• Mass (e.g., milligrams)
• Concentration (e.g., milligrams per milliliter)
• Both, where applicable

The stated content must match the value reported in the Certificate of Analysis (COA) on file with GIBQ.

The label must display a lot or batch identifier that is traceable to a specific Certificate of Analysis on file with GIBQ. The identifier must allow GIBQ to link the labeled product to its corresponding COA without ambiguity.

The following elements must NOT appear on the physical product label or immediate packaging. Presence of any prohibited element results in a fail determination for Point 7.

The label must not include dosing instructions, regimens, or guidance suggesting how the compound should be administered. This includes (without limitation): mass-per-bodyweight ratios, units per day, cycle lengths, peptide stacks, escalation protocols, or any directive language regarding administration.

The label must not include claims that the compound treats, prevents, cures, ameliorates, or affects any disease, condition, or biological state. This includes (without limitation): performance enhancement, anti-aging, weight management, cognitive improvement, or any claim implying clinical or therapeutic benefit.

The label must not include imagery depicting:

• Syringes contacting human skin
• Human muscle, body, or anatomical illustrations
• Before/after physiological depictions
• Medical procedure or clinical setting imagery

Imagery purely scientific or molecular in nature (e.g., chemical structure diagrams) is permitted.

The label must not employ visual design or naming conventions that mimic FDA-approved prescription pharmaceutical products. This includes (without limitation):

• Rx symbol or its visual variants
• NDC-style numbering systems
• Color schemes or layouts strongly associated with prescription drug packaging
• Naming or branding that implies FDA approval, prescription status, or pharmaceutical-grade certification

GIBQ evaluates compliance with this standard as follows:

1. Vendor submits high-resolution images or physical samples of product labels and immediate packaging for each SKU under audit.
2. GIBQ reviews submitted artifacts against the four required elements. Each element is independently verified.
3. GIBQ reviews submitted artifacts against the four prohibited elements. Any presence of a prohibited element is documented.
4. GIBQ renders a pass/fail determination for Point 7.

Point 7 outcome is binary.

There is no partial credit, no remediation period, and no conditional pass. A failing audit may be re-submitted following label revision, but the prior failure remains documented in the vendor's audit record.